Trial Profile
Pivotal phase III study of hepatic arterial infusion of melphalan with venous filtration via peripheral hepatic perfusion for the treatment of hepatocellular carcinoma.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 21 May 2013
Price :
$35
*
At a glance
- Drugs Melphalan (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Delcath Systems
- 21 May 2013 Pending a decision from the FDA, Delcath anticipate that this trial will commence by the end of 2013, according to the Delcath Q1 20-13 financial report.
- 25 Aug 2011 New trial record